Ensuring Representation: A Scoping Review of Interventions to Increase Minority Participation in Cancer-Related Research Fig 1. Selected recommendations regarding surgery, pathology, and germline ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

Only modest improvements in the systemic treatment of MPM patients have been made in the last decade, after the presentation of the results of the EMPHACIS Phase III study, which led to the ...

Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

Mesothelioma is a highly fatal disease with a survival rate of under 10% at five years. New advances with immunotherapy have improved survival, but only 23% of patients are alive at three years when ...

MTG Biotherapeutics (MTG), an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug ...

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results ...

Keytruda plus chemotherapy is now a first-line treatment for pleural mesothelioma, replacing chemotherapy alone as the standard of care. The KEYNOTE-483 trial showed significant improvements in ...

Prasad Adusumilli and colleagues have shown that CAR T cells that start to lose power can be revived by immunotherapy drugs given several weeks later. Mesothelioma is a rare cancer that affects the ...

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase ...

AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...